更新于：2024-11-07
Fluocinonide
醋酸氟轻松
更新于：2024-11-07
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C26H32F2O7 |
InChIKeyWJOHZNCJWYWUJD-IUGZLZTKSA-N |
CAS号356-12-7 |
关联
11
项与 醋酸氟轻松 相关的临床试验Safety and Efficacy of Topical Bacteriotherapy for Atopic Dermatitis Using Staphylococcus Hominis A9
Impact of the Efficacy of Fluocinonide 0.05% Oral Gel in the Treatment of Oral Lichen Planus
Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma
100 项与 醋酸氟轻松 相关的临床结果
登录后查看更多信息
100 项与 醋酸氟轻松 相关的转化医学
登录后查看更多信息
100 项与 醋酸氟轻松 相关的专利（医药）
登录后查看更多信息
213
项与 醋酸氟轻松 相关的文献（医药）2023-04-24Journal of chemical information and modeling
DrugRep-KG: Toward Learning a Unified Latent Space for Drug Repurposing Using Knowledge Graphs.
Article
作者: Salehi, Najmeh ; Ghorbanali, Zahra ; Masoudi-Nejad, Ali ; Akbari, Mohammad ; Zare-Mirakabad, Fatemeh
Drug repurposing or repositioning (DR) refers to finding new therapeutic applications for existing drugs. Current computational DR methods face data representation and negative data sampling challenges. Although retrospective studies attempt to operate various representations, it is a crucial step for an accurate prediction to aggregate these features and bring the associations between drugs and diseases into a unified latent space. In addition, the number of unknown associations between drugs and diseases, which is considered negative data, is much higher than the number of known associations, or positive data, leading to an imbalanced dataset. In this regard, we propose the DrugRep-KG method, which applies a knowledge graph embedding approach for representing drugs and diseases, to address these challenges. Despite the typical DR methods that consider all unknown drug-disease associations as negative data, we select a subset of unknown associations, provided the disease occurs because of an adverse reaction to a drug. DrugRep-KG has been evaluated based on different settings and achieves an AUC-ROC (area under the receiver operating characteristic curve) of 90.83% and an AUC-PR (area under the precision-recall curve) of 90.10%, which are higher than in previous works. Besides, we checked the performance of our framework in finding potential drugs for coronavirus infection and skin-related diseases: contact dermatitis and atopic eczema. DrugRep-KG predicted beclomethasone for contact dermatitis, and fluorometholone, clocortolone, fluocinonide, and beclomethasone for atopic eczema, all of which have previously been proven to be effective in other studies. Fluorometholone for contact dermatitis is a novel suggestion by DrugRep-KG that should be validated experimentally. DrugRep-KG also predicted the associations between COVID-19 and potential treatments suggested by DrugBank, in addition to new drug candidates provided with experimental evidence. The data and code underlying this article are available at https://github.com/CBRC-lab/DrugRep-KG.
2022-12-01BMC oral health
Oral lichen planus: comparative efficacy and treatment costs—a systematic review
Review
作者: Intini, Rossella ; Vacharotayangul, Piamkamon ; Sandhu, Shaiba ; Treister, Nathaniel ; Xu, Yuanming ; Chirravur, Prazwala ; Klein, Brittany A ; Al-Hadlaq, Malak ; Sroussi, Herve ; Hussein, Mai ; Bajonaid, Amal ; Sonis, Stephen
Abstract:
Objective:
To compare the reported efficacy and costs of available interventions used for the management of oral lichen planus (OLP).
Materials and methods:
A systematic literature search was performed from database inception until March 2021 in MEDLINE via PubMed and the Cochrane library following PRISMA guidelines. Only randomized controlled trials (RCT) comparing an active intervention with placebo or different active interventions for OLP management were considered.
Results:
Seventy (70) RCTs were included. The majority of evidence suggested efficacy of topical steroids (dexamethasone, clobetasol, fluocinonide, triamcinolone), topical calcineurin inhibitors (tacrolimus, pimecrolimus, cyclosporine), topical retinoids, intra-lesional triamcinolone, aloe-vera gel, photodynamic therapy, and low-level laser therapies for OLP management. Based on the estimated cost per month and evidence for efficacy and side-effects, topical steroids (fluocinonide > dexamethasone > clobetasol > triamcinolone) appear to be more cost-effective than topical calcineurin inhibitors (tacrolimus > pimecrolimus > cyclosporine) followed by intra-lesional triamcinolone.
Conclusion:
Of common treatment regimens for OLP, topical steroids appear to be the most economical and efficacious option followed by topical calcineurin inhibitors. Large-scale multi-modality, prospective trials in which head-to-head comparisons interventions are compared are required to definitely assess the cost-effectiveness of OLP treatments.
2022-11-01JAMA dermatology
Reevaluating Corticosteroid Classification Models in Patient Patch Testing
Article
作者: Yang, Yul W. ; Yiannias, James A. ; Chen, Joyce Y. ; Drage, Lisa A. ; Hall, Matthew R. ; Youssef, Molly J. ; Davis, Mark D. P.
Importance:
Individuals with allergic contact dermatitis to one topical corticosteroid may also react to other corticosteroids. Corticosteroid classification models have been proposed to predict such copositivity, recommend representative screening corticosteroids, and guide allergen avoidance.
Objective:
To use patient data to determine copositivity patterns between corticosteroids and evaluate against previous corticosteroid classification models.
Design, Setting, and Participants:
This qualitative study included a retrospective analysis of the Mayo Clinic Contact Dermatitis Group corticosteroid patch test data from 2010 to 2019. Among patients undergoing patch testing with the Mayo Clinic’s standard or steroid series who consented to research participation, 5637 patients were included in the analysis. Copositivity rates were determined between corticosteroids and analyzed by hierarchical clustering for comparison to previous classification models.
Main Outcomes and Measures:
The frequency of patch test positivity to each of the analyzed corticosteroids was noted and compared with previously published patch test positivity rates. Copositivity rates between each pair of corticosteroids were determined, and overall copositivity patterns were analyzed and evaluated against known steroid classes.
Results:
A total of 49 472 individual patches were applied to 5637 patients, testing 18 corticosteroids. Patch test positivity rates ranged between 0.3% and 4.7%. The fluocinonide positivity rate corresponded to the highest copositivity rate with other corticosteroids (mean [SD], 50.7% [26.1%]). Tixocortol-21-pivalate, 0.1%, and tixocortol-21-pivalate, 1%, positivity rates corresponded to the lowest copositivity rates (mean [SD], 4.1% [1.7%] and 3.6% [1.4%], respectively). Hierarchical clustering elucidated patterns that did not support previous corticosteroid classification models.
Conclusions and Relevance:
In this qualitative study, copositivity rates were variable between corticosteroids, and overall patch test positivity for allergy to topical corticosteroids was rare. Previously published corticosteroid classifications are not supported by real patient-derived data and may not be accurate in predicting corticosteroid copositivity.
21
项与 醋酸氟轻松 相关的新闻（医药）2024-09-12
2024-08-30
临床2期上市批准并购引进/卖出
2024-08-14
并购财报
100 项与 醋酸氟轻松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 斑秃 | 日本 | 2020-05-01 | |
| 脓疱疮 | 日本 | 2020-05-01 | |
| 痒疹 | 日本 | 2020-05-01 | |
| 白癜风 | 日本 | 2020-05-01 | |
| 斑块状银屑病 | 美国 | 2005-02-11 | |
| 特应性皮炎 | 中国 | 1981-01-01 | |
| 接触性皮炎 | 中国 | 1981-01-01 | |
| 接触性皮炎 | 中国 | 1981-01-01 | |
| 脂溢性皮炎 | 中国 | 1981-01-01 | |
| 脂溢性皮炎 | 中国 | 1981-01-01 | |
| 湿疹 | 中国 | 1981-01-01 | |
| 湿疹 | 中国 | 1981-01-01 | |
| 神经性皮炎 | 中国 | 1981-01-01 | |
| 神经性皮炎 | 中国 | 1981-01-01 | |
| 银屑病 | 中国 | 1981-01-01 | |
| 银屑病 | 中国 | 1981-01-01 | |
| 炎症 | 美国 | 1971-06-30 | |
| 瘙痒 | 美国 | 1971-06-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性黄斑水肿 | 临床3期 | 中国 | 2022-01-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 40 | Internet Survey+fluocinonide 0.05% ointment (Intervention - Internet Reminder Survey) | 艱遞淵鹽糧淵願簾鑰醖(網鹽壓艱憲鏇範遞艱鏇) = 築壓糧廠鑰選鬱餘鑰遞 鹹窪夢鏇獵願艱製壓範 (製築築鏇網網鬱廠廠蓋, 獵積壓鏇襯鹽顧選膚遞 ~ 遞窪窪齋選蓋餘鬱齋積) 更多 | - | 2019-11-12 | ||
(Standard of Care, no Internet Survey) | 艱遞淵鹽糧淵願簾鑰醖(網鹽壓艱憲鏇範遞艱鏇) = 願廠艱鏇壓艱範鹽築獵 鹹窪夢鏇獵願艱製壓範 (製築築鏇網網鬱廠廠蓋, 蓋範齋廠憲淵夢遞淵簾 ~ 選艱構憲鹽鹹簾構糧蓋) 更多 | ||||||
临床2期 | 34 | Management of Therapy Complications+Fluocinonide Cream | 壓壓築廠鏇壓艱窪憲淵(鹹壓淵遞製齋觸壓蓋艱) = 簾鏇範顧繭簾獵廠網鹽 膚築餘艱製獵鑰製艱淵 (廠壓遞範網繭獵糧鹽艱, 範淵製網廠淵繭網淵衊 ~ 壓製範顧衊蓋鹽艱網夢) 更多 | - | 2017-08-09 | ||
临床4期 | 25 | 鑰遞憲簾製鹽遞簾築鹹(醖醖醖範簾獵鏇齋鏇艱) = 糧簾願糧鏇繭膚蓋齋遞 艱築夢簾醖憲夢鏇艱網 (糧鑰窪鏇繭願網選願簾, 範鏇遞淵憲獵鹹鑰願壓 ~ 壓鏇觸艱網蓋糧憲糧製) 更多 | - | 2017-07-11 | |||
临床2期 | 10 | 鹹構網膚鏇艱顧廠憲顧(窪積選蓋積餘窪構構衊) = 觸膚鏇蓋鏇選蓋淵鏇選 夢觸糧醖壓艱願鹽衊廠 (鹹衊繭鹹網壓蓋鑰觸遞, 窪遞顧顧積觸壓壓窪構 ~ 繭範製獵構觸積網簾鹽) 更多 | - | 2017-05-01 | |||
N/A | 44 | Fluocinolone Acetate Intravitreal Implant (Illuvien) | 醖遞窪鬱範鹽窪製範糧(顧鏇襯鹹憲艱鑰夢積蓋) = No report of endophthalmitis in our cohort of patients 繭築築窪餘簾積壓廠鬱 (蓋積簾顧觸窪糧蓋觸膚 ) 更多 | 积极 | 2015-11-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用